CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Long-term efficacy and safety of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes
DOI 10.1055/s-0035-1549681
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Roden, L Merker, F Roux, A Salsali, G Kim, P Stella, HJ Woerle, UC Broedl
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aim: Assess long-term safety and efficacy of empagliflozin monotherapy versus placebo and sitagliptin in patients with type 2 diabetes. Methods: Of 899 patients treated with empagliflozin 10 mg, empagliflozin 25 mg, placebo or sitagliptin 100 mg for 24 weeks (EMPA-REG MONO™), 68.4% continued in a Phase-III double-blind extension (EMPA-REG EXTEND™ MONO) for ≥52 weeks (until last patient treated for 76 weeks). Explora…
Zitieren
Zitierempfehlung
M Roden, L Merker, F Roux, A Salsali, G Kim, P Stella, HJ Woerle, UC Broedl (2015) Long-term efficacy and safety of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0035-1549681
Mit CareLit weiterarbeiten